Aliases & Classifications for Myofascial Pain Syndrome

MalaCards integrated aliases for Myofascial Pain Syndrome:

Name: Myofascial Pain Syndrome 12 15 17
Myofascial Pain Syndromes 44 70
Myofascial Pain Dysfunction Syndrome 54
Fibromyalgia 70

Classifications:



External Ids:

Disease Ontology 12 DOID:431
MeSH 44 D009209
UMLS 70 C0016053 C0027073

Summaries for Myofascial Pain Syndrome

MalaCards based summary : Myofascial Pain Syndrome, also known as myofascial pain syndromes, is related to fibromyalgia and glossopharyngeal neuralgia, and has symptoms including muscle weakness, fatigue and myoclonus. An important gene associated with Myofascial Pain Syndrome is POMC (Proopiomelanocortin), and among its related pathways/superpathways are CREB Pathway and G-protein signaling RAC1 in cellular process. The drugs Gabapentin and Etoricoxib have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, spinal cord and cortex, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 73 Myofascial pain syndrome (MPS), also known as chronic myofascial pain (CMP), is a syndrome characterized... more...

Related Diseases for Myofascial Pain Syndrome

Diseases related to Myofascial Pain Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Related Disease Score Top Affiliating Genes
1 fibromyalgia 31.6 POMC NGF CALCA BDNF
2 glossopharyngeal neuralgia 30.7 TAC1 POMC
3 facial neuralgia 30.5 TAC1 LAPTM4A
4 radiculopathy 30.3 TAC1 LAPTM4A
5 hypochondriasis 30.2 POMC BDNF
6 frozen shoulder 30.2 LAPTM4A ASIC3
7 complex regional pain syndrome 30.1 TAC1 POMC CALCA
8 pulpitis 30.1 TRPV1 KNG1
9 sleep disorder 30.0 TAC1 POMC BDNF
10 bursitis 29.8 TAC1 LAPTM4A KNG1 CALCA
11 anxiety 29.5 TAC1 POMC NGF BDNF
12 reflex sympathetic dystrophy 29.4 TRPV1 TAC1 LAPTM4A KNG1 CALCA
13 algoneurodystrophy 29.4 TAC1 NGF KNG1 CALCA
14 major depressive disorder 29.3 TAC1 POMC NGF BDNF
15 irritable bowel syndrome 29.2 TRPV1 TAC1 POMC NGF BDNF
16 somatoform disorder 29.0 TRPV1 TAC1 NGF LAPTM4A CALCA BDNF
17 paine syndrome 28.8 TRPV1 TAC1 NGF LAPTM4A KNG1 CALCA
18 trigeminal neuralgia 28.8 TRPV1 TAC1 NGF KNG1 CALCA BDNF
19 peripheral nervous system disease 28.3 TRPV1 TAC1 POMC NGF KNG1 CALCA
20 chronic pain 10.6
21 trichorhinophalangeal syndrome 10.5
22 bruxism 10.4
23 chronic fatigue syndrome 10.4
24 patellofemoral pain syndrome 10.3 TAC1 LAPTM4A
25 neurodermatitis 10.3 TAC1 POMC
26 arachnoiditis 10.3 TAC1 POMC
27 somatization disorder 10.3 TAC1 POMC
28 shoulder impingement syndrome 10.3 TAC1 LAPTM4A
29 ectopic cushing syndrome 10.3 POMC CALCA
30 carbamazepine allergy 10.3 TAC1 CALCA
31 taylor's syndrome 10.3 TAC1 CALCA
32 nasal cavity adenocarcinoma 10.2 POMC CALCA
33 motion sickness 10.2 TAC1 POMC
34 interval angle-closure glaucoma 10.2 TAC1 KNG1
35 graves disease 1 10.2 POMC CALCA
36 intracranial vasospasm 10.2 TAC1 KNG1
37 autonomic dysfunction 10.2
38 headache 10.2
39 spasticity 10.2
40 acute apical periodontitis 10.2 TAC1 KNG1
41 sick building syndrome 10.2 TRPV1 POMC
42 akinetopsia 10.2 TAC1 KNG1
43 hyperhidrosis, gustatory 10.2 TRPV1 TAC1
44 facial dermatosis 10.2 TRPV1 TAC1
45 pseudopterygium 10.2 TRPV1 TAC1
46 atypical depressive disorder 10.2 POMC BDNF
47 thyroid gland medullary carcinoma 10.2 POMC CALCA
48 retrograde amnesia 10.2 POMC BDNF
49 fasciitis 10.2
50 48,xyyy 10.2

Graphical network of the top 20 diseases related to Myofascial Pain Syndrome:



Diseases related to Myofascial Pain Syndrome

Symptoms & Phenotypes for Myofascial Pain Syndrome

UMLS symptoms related to Myofascial Pain Syndrome:


muscle weakness; fatigue; myoclonus; back pain; myalgia; torticollis; pain; chronic pain; sciatica; muscle cramp; muscle rigidity; muscle spasticity; myofascial trigger point pain

GenomeRNAi Phenotypes related to Myofascial Pain Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.36 POMC
2 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.36 NGF
3 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.36 NGF
4 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.36 NGF
5 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.36 NGF
6 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.36 LAPTM4A POMC
7 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.36 NGF
8 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.36 LAPTM4A
9 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.36 LAPTM4A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.36 POMC

MGI Mouse Phenotypes related to Myofascial Pain Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 ASIC3 BDNF EPHB1 KNG1 NGF PDGFRB
2 integument MP:0010771 9.5 ASIC3 BDNF NGF PDGFRB POMC TAC1
3 nervous system MP:0003631 9.23 ASIC3 BDNF EPHB1 LAPTM4A NGF PDGFRB

Drugs & Therapeutics for Myofascial Pain Syndrome

Drugs for Myofascial Pain Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 297)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
3
Perphenazine Approved Phase 4 58-39-9 4748
4
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
6
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
7
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
10
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
11
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
12
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
13
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
14
Flunarizine Approved Phase 4 52468-60-7 941361
15
Amitriptyline Approved Phase 4 50-48-6 2160
16
Acetaminophen Approved Phase 4 103-90-2 1983
17
Citalopram Approved Phase 4 59729-33-8 2771
18
Ibuprofen Approved Phase 4 15687-27-1 3672
19
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
20
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
21
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
22
Ethanol Approved Phase 4 64-17-5 702
23
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
24
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
25
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
26
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
27
Promethazine Approved, Investigational Phase 4 60-87-7 4927
28
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
29
Suvorexant Approved, Investigational Phase 4 1030377-33-3
30
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
31
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
32
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
33
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
34
Dexetimide Withdrawn Phase 4 21888-98-2
35 Cyclooxygenase 2 Inhibitors Phase 4
36 Gastrointestinal Agents Phase 4
37 Antiemetics Phase 4
38 Antipsychotic Agents Phase 4
39 Quetiapine Fumarate Phase 4 111974-72-2
40 Central Nervous System Stimulants Phase 4
41 Cytochrome P-450 Enzyme Inhibitors Phase 4
42
Histamine Phosphate Phase 4 51-74-1 65513
43 Histamine H1 Antagonists Phase 4
44 Histamine Antagonists Phase 4
45 Citrate Phase 4
46 Anesthetics, Intravenous Phase 4
47 Anesthetics, General Phase 4
48 Excitatory Amino Acid Antagonists Phase 4
49 Trace Elements Phase 4
50 Nutrients Phase 4

Interventional clinical trials:

(show top 50) (show all 841)
# Name Status NCT ID Phase Drugs
1 An Eight Week, Double-Blind Efficacy Study of Cyclobenzaprine ER (Amrix TM) Augmentation to Alleviate Fibromyalgia Fatigue and Muscle Pain Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
2 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
3 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? A Randomized, Double-blinded, Placebo-controlled, Crossover Study. Unknown status NCT02806440 Phase 4 Low dose naltrexone;Placebo
4 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
5 Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia Completed NCT01226667 Phase 4 Pregabalin
6 Pool-based Exercise in Fibromyalgia Management: a Prospective Randomized Comparison Between Stretching and Ai Chi Completed NCT00550641 Phase 4
7 A Randomized Controlled Trial Comparing the Efficay and Tolerability of Ai Chi Versus Stretching in Fibromyalgia Management: a Six Months Study Completed NCT00600574 Phase 4
8 A Randomized, Pilot Clinical Trial to Assess the Comparative Efficacy and Tolerability of Quetiapine XR Versus Amitriptyline for the Treatment of Patients With Fibromyalgia Completed NCT00766350 Phase 4 amitriptyline;quetiapine
9 Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II) Completed NCT00791739 Phase 4 trazodone, pregabalin
10 The Study of Heart Rate Variability in Patients With Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
11 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
12 The Efficacy of Topical Thiocolchicoside in Cervical Myofascial Pain Syndrome: Triple-Arm, Single-Blind, Randomized, Prospective, Phase IV Clinical Study Completed NCT00272532 Phase 4 Thiocolchicoside
13 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial. Completed NCT01250184 Phase 4 Lidocaine injection
14 An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Milnacipran Completed NCT01125423 Phase 4 Milnacipran
15 A Pilot Study on the Combined Use of Cognitive Behavioral Therapy (CBT) and Milnacipran Completed NCT01038323 Phase 4 Educational with milnacipran
16 A Randomized, Double-Blind Comparison of Duloxetine 30 mg QD and Placebo in Adult Patients With Fibromyalgia Completed NCT00965081 Phase 4 Duloxetine;Placebo
17 Eszopiclone in the Treatment of Insomnia and Associated Symptoms of Fibromyalgia Completed NCT00392041 Phase 4 Eszopiclone;placebo
18 Quetiapine Compared With Placebo in the Management of Fibromyalgia Completed NCT01458964 Phase 4 Quetiapine
19 The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia Completed NCT01234675 Phase 4 Milnacipran;Placebo
20 A Randomized, Double-blind,Placebo-controlled, Two-way Crossover Study to Evaluate the Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging Activation Patterns in Patients With Fibromyalgia Completed NCT01173055 Phase 4 milnacipran;Placebo
21 Randomized, Double-blind, Placebo-controlled Trial to Measure the Efficacy and Safety of Vitamin D3 in Patients With Fibromyalgia. Completed NCT03369379 Phase 4 D3 Vitamin
22 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Switch Study to Evaluate the Safety, Tolerability and Efficacy of Milnacipran in Patients With an Inadequate Response to Duloxetine for the Treatment of Fibromyalgia Completed NCT01077375 Phase 4 Placebo;Milnacipran
23 Combining N-of-1 Trials to Assess Fibromyalgia Therapies Completed NCT00000428 Phase 4 Amitriptyline;Amitriptyline plus Fluoxitine
24 Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study Completed NCT00983320 Phase 4 quetiapine;placebo
25 A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia Completed NCT00965601 Phase 4
26 Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome: A Randomized, Double Blind, Parallel Group, Flexible Dose, Placebo Controlled Trial. Completed NCT00610610 Phase 4 Paroxetine CR;Placebo
27 Effects of a 12 Week Milnacipran 200 mg Treatment on Pain Perception and Pain Processing in Fibromyalgia - An Open Label Study Completed NCT01288807 Phase 4 Milnacipram
28 A 6-month, Open-label, Safety Trial Of Pregabalin In Adolescent Patients With Fibromyalgia Completed NCT01020526 Phase 4 pregabalin
29 A 15 Week, Randomized, Double Blind, Parallel-group, Placebo-controlled, Flexible-dose, Safety And Efficacy Study Of Pregabalin In Adolescents (12-17 Years Old) With Fibromyalgia Completed NCT01020474 Phase 4 placebo;pregabalin (Lyrica)
30 Perception of Discomfort and Psychosocial Difficulties in People With Diagnosis of Fibromyalgia and Predominant Neck Pain Completed NCT02078791 Phase 4 Botox infiltration
31 Ultracet (Tramadol HCL [37.5 mg]/Acetaminophen [325 mg]) Combination Tablets in the Treatment of the Pain of Fibromyalgia Completed NCT00766675 Phase 4 Tramadol hydrochloride;Acetaminophen
32 Effectiveness of Strengthening Exercises Using the Swiss Ball for Patients With Fibromyalgia: a Randomized Controlled Trial Completed NCT02063750 Phase 4
33 A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment Completed NCT01014585 Phase 4 Placebo;Milnacipran
34 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Quetiapine Fumarate Sustained Release(Seroquel SRTM) in the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome. Completed NCT00675896 Phase 4 Quetiapine Fumarate Sustained Release;Placebo
35 Flexible Dosed Duloxetine Versus Placebo in the Treatment of Fibromyalgia Completed NCT00673452 Phase 4 duloxetine hydrochloride;placebo
36 Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain: an Observational Prospective Study Completed NCT04123652 Phase 4 Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992
37 Probe Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome Completed NCT00241215 Phase 4 Botulinum toxin serotype A
38 The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles Completed NCT02230371 Phase 4 Granisetron;Control (placebo)
39 Plasma Rich in Growth Factors Effectiveness for Myofascial Pain Treatment in Masticatory Muscles: a Randomized Controlled Clinical Trial Completed NCT04040309 Phase 4 Lidocaine injection
40 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Completed NCT03271151 Phase 4 Cymbalta
41 Neurologic Signatures of Chronic Pain Disorders Completed NCT02747940 Phase 4 flunarizine and/or pregabalin
42 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
43 Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial. Recruiting NCT04704297 Phase 4 Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.;Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.;Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
44 Efficacy and Tolerability of Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients: A Double-blind, Randomized, Placebo-controlled Clinical Trial Recruiting NCT04488926 Phase 4 Standard Therapy;Rescue Drug
45 Magnesium Sulphate Injection in Treatment of Myofascial Trigger Points in Masseter Muscle Recruiting NCT04742140 Phase 4 Magnesium sulfate;Saline
46 Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) Recruiting NCT04245748 Phase 4 Escitalopram;Duloxetine
47 Anti-CGRP Neutralizing Antibody for Modulation of Neurogenic Inflammation in Trigeminal and Glossopharyngeal Pain Associated With Small Fiber Neuropathy/Fibromyalgia Recruiting NCT04158752 Phase 4 Galcanezumab
48 Effectiveness, Cost-utility and Neurobiological Effects of Low-dose Naltrexone in Patients With Fibromyalgia (INNOVA Project) Not yet recruiting NCT04739995 Phase 4 Low-dose naltrexone
49 Local Injection of Lidocaine Versus Ischemic Compression in Treatment of Woman With Chronic Pelvic Pain Caused by Abdominal Myofascial Pain Syndrome: Randomized Clinical Trial. Terminated NCT00628355 Phase 4 lidocaine
50 A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone

Search NIH Clinical Center for Myofascial Pain Syndrome

Cochrane evidence based reviews: myofascial pain syndromes

Genetic Tests for Myofascial Pain Syndrome

Anatomical Context for Myofascial Pain Syndrome

MalaCards organs/tissues related to Myofascial Pain Syndrome:

40
Skeletal Muscle, Spinal Cord, Cortex, Amygdala, Pineal, Brain, Skin

Publications for Myofascial Pain Syndrome

Articles related to Myofascial Pain Syndrome:

(show top 50) (show all 830)
# Title Authors PMID Year
1
Effects of diaphragm muscle treatment in shoulder pain and mobility in subjects with rotator cuff injuries: A dataset derived from a pilot clinical trial. 61
33665260 2021
2
Effectiveness of Dry Needling with Percutaneous Electrical Nerve Stimulation of High Frequency Versus Low Frequency in Patients with Myofascial Neck Pain. 61
33740346 2021
3
An unusual complication of quadriparesis after trigger point injection: a case report. 61
33009247 2021
4
Pharyngeal airway dimension in patients before and after treatment of myofascial pain syndrome. 61
31007142 2021
5
Granisetron vs. lidocaine injection to trigger points in the management of myofascial pain syndrome: a double-blind randomized clinical trial. 61
33691056 2021
6
Ultrasound-Guided Erector Spinae Plane Block and Trapezius Muscle Injection for Myofascial Pain Syndrome. 61
33713473 2021
7
Comparison of the effects of extracorporeal shockwave treatment with kinesiological taping treatments added to exercise treatment in myofascial pain syndrome. 61
33682694 2021
8
The Effect of Extracorporeal Shock Wave Therapy on Pain Intensity and Neck Disability for Patients With Myofascial Pain Syndrome in the Neck and Shoulder: A Meta-Analysis of Randomized Controlled Trials. 61
32520797 2021
9
Specialty-Specific Diagnoses in Pediatric Patients With Postconcussion Syndrome: Experience From a Multidisciplinary Concussion Clinic. 61
33605602 2021
10
The association between exposure to domestic abuse in women and the development of syndromes indicating central nervous system sensitization: A retrospective cohort study using UK primary care records. 61
33559289 2021
11
The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTTION systematic review. 61
33383293 2021
12
Leiomyosarcoma of the small intestine presenting as abdominal myofascial pain syndrome (AMPS): case report. 61
32970610 2021
13
Comparative Effectiveness of Thai Herbal Formula (Thor-Ra-Nee-San-Tha-Kat) Versus Naproxen for Chronic Myofascial Pain: A Pilot Randomized-Controlled Trial. 61
33216613 2021
14
"Quantitative Ultrasound Texture Feature Changes with Conservative treatment of the Trapezius Muscle in female patients with Myofascial Pain Syndrome". 61
33480607 2021
15
Optimal duration of stretching exercise in patients with chronic myofascial pain syndrome: A randomized controlled trial. 61
33367925 2021
16
Quality and readability of online information on myofascial pain syndrome. 61
33714513 2021
17
Predictive factors of response in radial Extracorporeal Shock-waves Therapy for Myofascial and Articular Pain: A retrospective cohort study. 61
33492278 2021
18
A critical overview of the current myofascial pain literature - January 2021. 61
33714506 2021
19
Ultrasound-guided interventional procedures for myofascial trigger points: a systematic review. 61
33159004 2021
20
Effectiveness of extracorporeal shock wave therapy versus standard care in the treatment of neck and upper back myofascial pain: a single blinded randomised clinical trial. 61
32731757 2021
21
Criteria Used for the Diagnosis of Myofascial Trigger Points in Clinical Trials on Physical Therapy: Updated Systematic Review. 61
32841969 2020
22
Characteristics of chiropractic patients treated at the University of Johannesburg chiropractic student clinic and relevance to the educational process. 61
33316062 2020
23
Effects of cognitive behavioral therapy on orofacial pain conditions. 61
33298629 2020
24
Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection. 61
33374687 2020
25
Sonography-guided trigger point injections in abdominal myofascial pain syndrome. 61
33285730 2020
26
Neuroticism Traits and Anxiety Symptoms are Exhibited in Athletes With Chronic Gastrocnemius Myofascial Pain Syndrome. 61
33065704 2020
27
Quantitative response of healthy muscle following the induction of capsaicin: an exploratory randomized controlled trial. 61
33308274 2020
28
Moxibustion therapy on myofascial pain syndrome: An evidence-based clinical practice guideline. 61
33181637 2020
29
Myofascial Pain Syndrome and Its Relation to Trigger Points, Facial Form, Muscular Hypertrophy, Deflection, Joint Loading, Body Mass Index, Age and Educational Status. 61
33437714 2020
30
Prevalence And Impact Of Myofascial Pain Syndrome In Relapsing-Remitting Multiple Sclerosis And The Effects Of Local Anesthetic Injections For Short-Term Treatment. 61
33022587 2020
31
The pathophysiological nature of sarcomeres in trigger points in patients with myofascial pain syndrome: A preliminary study. 61
32841448 2020
32
The efficacy of fascial plane blocks for myofascial pain syndrome: do they achieve long-term results? 61
33271010 2020
33
Serum inflammatory and oxidative stress biomarkers levels are associated with pain intensity, pressure pain threshold and quality of life in myofascial pain syndrome. 61
33160410 2020
34
Transcranial direct current stimulation improves myofascial pain syndrome and chronic fatigue. 61
33213134 2020
35
Authors' Reply: Letter to the Editor Regarding "The Effectiveness of Dry Needling and Exercise Therapy in Patients with Dizziness Caused by Cervical Myofascial Pain Syndrome; Prospective Randomized Clinical Study". 61
32358610 2020
36
Comments on Aydin et al: The Effectiveness of Dry Needling and Exercise Therapy in Patients with Dizziness Caused by Cervical Myofascial Pain Syndrome; a Prospective Randomized Clinical Study. 61
32358602 2020
37
Effect of Physical Exercise Programs on Myofascial Trigger Points-Related Dysfunctions: A Systematic Review and Meta-analysis. 61
33011790 2020
38
Needling on trigger point promotes muscle regeneration after bupivacaine injection induced injury. 61
33132179 2020
39
Comparison of efficacy of corticosteroid injection versus extracorporeal shock wave therapy on inferior trigger points in the quadratus lumborum muscle: a randomized clinical trial. 61
33076888 2020
40
Ultrasound Imaging of Injections in Masseter Muscle without Contrast Agent Using Strain Elastography and a Novel B-Mode Spatiotemporal Filter. 61
32753287 2020
41
Erector spinae plane block and rhomboid intercostal block for the treatment of post-mastectomy pain syndrome. 61
33447197 2020
42
The Levels of Insulin-Like Growth Factor in Patients with Myofascial Pain Syndrome and in Healthy Controls. 61
33026183 2020
43
An electroencephalography (EEG) study of short-term electromyography (EMG) biofeedback training in patients with myofascial pain syndrome in the upper trapezius. 61
33132529 2020
44
A systematic review of musculoskeletal complaints, symptoms, and pathologies related to mobile phone usage. 61
32861360 2020
45
Extra-spinal sciatica and sciatica mimics: a scoping review. 61
32989195 2020
46
The assessment of affective temperament and life quality in myofascial pain syndrome patients. 61
33084454 2020
47
Ultrasound measurements of superficial and deep masticatory muscles in various postures: reliability and influencers. 61
32873849 2020
48
Chronic Facial Pain: Trigeminal Neuralgia, Persistent Idiopathic Facial Pain, and Myofascial Pain Syndrome-An Evidence-Based Narrative Review and Etiological Hypothesis. 61
32992770 2020
49
Treatment and management of myofascial pain syndrome. 61
33004157 2020
50
Ashi Acupuncture Versus Local Anesthetic Trigger Point Injections in the Treatment of Abdominal Myofascial Pain Syndrome: A Randomized Clinical Trial. 61
32967393 2020

Variations for Myofascial Pain Syndrome

Expression for Myofascial Pain Syndrome

Search GEO for disease gene expression data for Myofascial Pain Syndrome.

Pathways for Myofascial Pain Syndrome

Pathways related to Myofascial Pain Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.8 TRPV1 PDGFRB NGF EPHB1 BDNF
2
Show member pathways
11.55 PDGFRB NGF EPHB1 BDNF
3 11.54 TAC1 NGF BDNF
4
Show member pathways
11.51 TRPV1 NGF KNG1 ASIC3
5 10.87 TRPV1 NGF
6 10.46 PDGFRB NGF EPHB1 BDNF

GO Terms for Myofascial Pain Syndrome

Cellular components related to Myofascial Pain Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 TAC1 POMC NGF KNG1 CALCA BDNF
2 extracellular region GO:0005576 9.5 TAC1 POMC NGF KNG1 EPHB1 CALCA
3 dendrite GO:0030425 9.46 TRPV1 NGF EPHB1 BDNF
4 intrinsic component of plasma membrane GO:0031226 9.32 TRPV1 PDGFRB
5 axon GO:0030424 9.02 TAC1 NGF EPHB1 CALCA BDNF

Biological processes related to Myofascial Pain Syndrome according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.99 TAC1 POMC PDGFRB KNG1 CALCA
2 inflammatory response GO:0006954 9.85 TRPV1 TAC1 KNG1 CALCA
3 positive regulation of apoptotic process GO:0043065 9.84 TRPV1 PDGFRB NGF KNG1
4 cell-cell signaling GO:0007267 9.78 TAC1 POMC CALCA
5 neuropeptide signaling pathway GO:0007218 9.67 TAC1 POMC CALCA
6 modulation of chemical synaptic transmission GO:0050804 9.63 NGF EPHB1 BDNF
7 regulation of blood pressure GO:0008217 9.61 TAC1 POMC CALCA
8 regulation of neuron differentiation GO:0045664 9.6 NGF BDNF
9 peripheral nervous system development GO:0007422 9.58 NGF BDNF
10 vasodilation GO:0042311 9.58 KNG1 CALCA
11 response to heat GO:0009408 9.58 TRPV1 CALCA ASIC3
12 neurotrophin TRK receptor signaling pathway GO:0048011 9.57 NGF BDNF
13 nerve development GO:0021675 9.56 NGF BDNF
14 positive regulation of cytosolic calcium ion concentration GO:0007204 9.56 TRPV1 TAC1 KNG1 CALCA
15 nerve growth factor signaling pathway GO:0038180 9.52 NGF BDNF
16 negative regulation of heart rate GO:0010459 9.51 TRPV1 TAC1
17 cellular response to nerve growth factor stimulus GO:1990090 9.5 TRPV1 TAC1 CALCA
18 positive regulation of collateral sprouting GO:0048672 9.48 NGF BDNF
19 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.46 PDGFRB NGF EPHB1 BDNF
20 detection of chemical stimulus involved in sensory perception of pain GO:0050968 9.37 TRPV1 ASIC3
21 response to pain GO:0048265 9.13 TRPV1 TAC1 CALCA
22 detection of temperature stimulus involved in sensory perception of pain GO:0050965 8.92 TRPV1 EPHB1 CALCA ASIC3

Molecular functions related to Myofascial Pain Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.1 POMC PDGFRB NGF KNG1 CALCA BDNF
2 nerve growth factor receptor binding GO:0005163 8.96 NGF BDNF

Sources for Myofascial Pain Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....